Post Profile






MD Anderson-led study finds ribociclib improves progression-free survival for women with metastatic breast cancer

(University of Texas M. D. Anderson Cancer Center) In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, ribociclib, in combination with the aromatase inhibitor letrozole, dramatically improved progression-free survival of post-menopausal women with hormone receptor-positive metastatic breast cancer, compared to the hormone therapy alone.
read more

share

Related Posts


Tyverb(R)/Tykerb(R) Plus Letrozole Significantly Delayed Disease Progression In Post-menopausal Women With ErbB2 Positive Metastatic Breast Cancer

Health : Medical News Today

New results from a study in metastatic breast cancer showed that the combination of Tyverb®/Tykerb® (lapatinib) plus letrozole as a first line treatment regimen provided a significant improvement in delaying disease progression when...

Ribociclib improves progression-free survival in advanced breast cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast can...

Custirsen shows no survival benefits in metastatic prostate cancer

Diseases & Conditions / Cancer : EurekAlert: Cancer

(European Society for Medical Oncology) A phase III randomized controlled trial of custirsen in combination with cabazitaxel/prednisone in patients with previously-treated metastatic, castration-resistant prostate cancer has shown n...

Combination of Everolimus and Exemestane Improves Progression-Free Survival for Women with Metastatic Breast Cancer

Health : Newswise Medical News

In an international Phase III randomized study, everolimus, when combined with the hormonal therapy exemestane, has been shown to dramatically improve progression-free survival, according to research from The University of Texas MD ...

Ribociclib Improves Progression-Free Survival for Women with Metastatic Breast Cancer

Health : Newswise Medical News

In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, ribociclib, in combination with the aromatase inhibitor letrozole, dramatically improved progression-free survival (PFS) of po...

Comments


Copyright © 2016 Regator, LLC